Expanding analyst interest in ORYZON

by Oryzon Genomics

New U.S. investment bank joins, bringing total coverage to ten analysts

Read more

ORYZON continues to strengthen its patent portfolio for the vafidemstat

by Oryzon Genomics

It has been today announced that they has received “Decision to grant” communications from the Canadian Intellectual Property Office and the Israel Patent Office for its patent applications CA3071...

Read more

ORYZON to host virtual KOL event on July 9, 2025

by Oryzon Genomics

To discuss the unmet medical need in Borderline Personality Disorder (BPD) and the design of vafidemstat’s Phase III PORTICO-2 trial in BPD

Read more

ORYZON to attend the 2025 Phelan-McDermid Syndrome (PMS) Congress in Barcelona on June 26-29

by Oryzon Genomics

Agitation/Aggression in PMS and other ASD-related patient subpopulations are the main focus of Oryzon’s VANDAM project included in the Med4Cure IPCEI project

Read more

ORYZON to provide corporate progress updates at several events in May - June

by Oryzon Genomics

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its management will give an update on corporate progress at several intern...

Read more

ORYZON reports financial results and corporate update for quarter ended March 31, 2025

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today reported financial results for the first quarter ended Marc...

Read more

ORYZON awarded 13.26 million € through the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)

by Oryzon Genomics

Oryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases

Read more

ORYZON Raises €30 Million in Capital Increase

by Oryzon Genomics

It has been announced today the successful completion of a €30 million capital increase through the issuance of 12,765,958 new shares, priced at €2.35 per share. This pricing reflects a 15.44%

Read more

ORYZON continues to strengthen its patent portfolio for vafidemstat.

by Oryzon Genomics

The patent, titled “Methods of treating Attention Deficit Hyperactivity Disorder using KDM1A inhibitors such as the compound vafidemstat”, covers the use Oryzon’s LSD1 inhibitor, vafidemstat, cu...

Read more

ORYZON announces first patient dosed in NCI-sponsored Phase I/II clinical trial of iadademstat plus immune checkpoint inhibitors in 1L extensive stage Small Cell Lung Cancer

by Oryzon Genomics

Oryzon Genomics announced today that the first patient has been dosed in a Phase I/II trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in combination with immune checkpoint inhibi...

Read more

Oryzon renueva su compromiso con la Alianza para la Vacunación Infantil

by Oryzon Genomics

La compañía se suma nuevamente a la iniciativa impulsada por la Fundación "la Caixa" en colaboración con Gavi, the Vaccine Alliance. Esta acción solidaria respalda el ODS3 de las Naciones Unidas,...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

New breakthrough in developing more pers...

by Universitat de Barcelona

The results show that adenocarcinoma exhibits much more active and fun...

Photos Stream